AcelRx Pharmaceuticals (ACRX) has its PDUFA date the day before on the 12th.  Its compound ARX-04 is up for approval to treat moderate-to-severe acute pain following a surgical procedure.  This is a crowded space and there are much more diverse views on whether this compound will be approved.  I don't own or have opinion on this name, but stock is likely to be very volatile this week depending on which way the decision goes due to the greater uncertainty.